Navigation Links
Another Study Links Fluoride to Bone Cancer
Date:4/29/2009

NEW YORK, April 29 /PRNewswire-USNewswire/ -- Blood fluoride levels were significantly higher in patients with osteosarcoma than in control groups, according to research published in Biological Trace Element Research (April 2009). Osteosarcoma, a rare bone cancer, occurs mostly in children and young adults.

Randhu and colleagues measured serum fluoride levels in three equal groups of age-matched and sex-matched patients. Group one had osteosarcoma, group two had non-osteosarcoma bone tumors, and group three had musculo-skeletal pain.(1)

"Mean serum fluoride concentration was found to be significantly higher in patients with osteosarcoma as compared to the other two groups," writes Randhu's team. "(T)his report proves a link between raised fluoride levels in serum and osteosarcoma," they write.

This reinforces a 2006 published Harvard study by Bassin showing a link between water fluoridation and osteosarcoma in young boys.(2)

A 1992 New Jersey Department of Health study shows osteosarcoma rates higher among young males in fluoridated vs. unfluoridated regions of New Jersey.(3)

More studies link fluoride to bone and other cancers but are downplayed or ignored by government officials.(4)(5)

Bone defects similar to bone cancer were detected in fluoridated Newburgh, NY children as early as 1955. Newburgh is home of the first human health fluoridation experiment begun in 1945.

According to Christopher Bryson in The Fluoride Deception, "A radiologist, Dr. John Caffey of Columbia University, called the defects 'striking' in their 'similarity' to bone cancer... and seen more than twice as frequently among boys in Newburgh as among boys in nonfluoridated Kingston [the control city]."(6)

In 2006, the prestigious National Research Council review of fluoride/fluoridation toxicology found
'/>"/>

SOURCE NYS Coalition Opposed to Fluoridation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Viatronix V3D-Colon Utilized in Another Landmark Study
2. Another LNA-based RNA Inhibitor Enters Clinical Trials
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
10. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 26, 2014 Investor-Edge has initiated ... VVUS ), Horizon Pharma PLC (NASDAQ: HZNP ), ... (NYSE: JNJ ), and Theravance Inc. (NASDAQ: ... be accessed at: http://investor-edge.com/register . On Tuesday, ... 0.07%, the Dow Jones Industrial Average edged 0.02% lower, to ...
(Date:11/26/2014)... A hernia is condition in which ... the wall of a weak muscle area. Obesity, poor nutrition, ... of the causes of hernias. There are several types of ... inguinal hernia is when part of the abdominal tissue/organ protrudes ... the area of the umbilicus. A hiatal hernia is when ...
(Date:11/26/2014)... Calif. , Nov. 26, 2014  Aridis ... to produce novel therapies for infectious diseases, announced ... M.D., an internationally recognized key opinion leader in ... Company,s scientific advisory board. Founder and ... stated, "We believe Dr. Opal,s extensive experience investigating ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 2Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 3Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 4Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... a leading developer of innovative catheters and stents for ... closing of a $17M Round D financing.  The financing ... based EDB Investments (,EDBI,) with strong support from current ... are delighted to have Bio*One join our group of ...
... Arable Corporation ( www.arablecorp.com ) has announced the launch ... the clinical trial industry.  Whereas traditional CTMS systems have ... CTMS and EDC capabilities without the traditionally high start-up ... or CROs to manage the planning and implementation of ...
Cached Medicine Technology:TriReme Medical Announces $17 Million Series D Financing 2Arable Corporation Announces New Technology for Clinical Trial Industry 2
(Date:11/27/2014)... November 27, 2014 Now that Thanksgiving ... has officially launched, Emassagechair.com has announced its ... Discount Event. , Negotiating on behalf of their ... massage chair brands, Emassagechair.com has generated significant buzz in ... and biggest discounts yet. , Shoppers are excited for ...
(Date:11/27/2014)... 2014 VogueQueen.com is making every effort ... across the world. As the premier online supplier of ... proud to release a huge selection of sexy prom ... it is also providing many beautiful styles in its ... at discounted prices. , “VogueQueen.com hopes to provide ...
(Date:11/27/2014)... Viejo, California (PRWEB) November 27, 2014 Developers ... announced a new plugin entitled ProPip, taking FCPX to the ... in picture effect with a few clicks of a mouse,” ... a time saver that our users will appreciate.” , With ... full customization leaving the possibilities truly endless. ProPip is great ...
(Date:11/27/2014)... 27, 2014 HealthPostures, a ... equipment , has announced that it has entered ... Environments. The partnership will put HealthPostures' products into ... , In addition to having its products sold ... promotes HealthPostures' products with the business decision makers ...
(Date:11/27/2014)... November 27, 2014 At The Little ... So it came as no surprise when a recent ... child’s academic success. The Journal of Pediatrics ... and motor tasks during the school years may be ... academic development.” The study monitored two groups of children; ...
Breaking Medicine News(10 mins):Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
... Care at the 15th SPSSCS Annual Meeting , ... New York, NY ... Specialists (SPSSCS) celebrates its 15th Annual Meeting - Play the Winning Hand: ... Vegas, NV. The meeting offers educational seminars for nurses, aestheticians ...
... Aeroportuario del Sureste, S.A.B. de C.V. (NYSE: ASR ... in Mexico and operator of Cancun Airport and eight others ... 26, 2009 the Mexican Secretary of Health confirmed the presence ... 28, 2009 the World Health Organization (the "WHO") acknowledged the ...
... Executive Chairman & CEO Douglas MacLellan offers expert insight ... April 29 AMDL Inc. ... major operations in China, announced today its Executive Chairman ... featured in The Wall Street Transcript - ...
... 23 June 2009, the Prostate Cancer Translational Research ... the Beurs van Berlage in Amsterdam (NL). Translational ... or population studies into clinical applications to reduce ... Association of Urology (EAU) provides an excellent forum ...
... Sales & Marketing Data In One Screen To ... Custom Metrics EWING, N.J., April 29 Archi-Tech ... reporting solutions, today announced the availability of managed ... portal for pharmaceutical sales reporting. Using InView, managed ...
... New analyses of data from the 16-Year ... by Bayer HealthCare Pharmaceuticals, were presented at the ... The study results showed that early and ... multiple sclerosis (MS) were more likely to avoid ...
Cached Medicine News:Health News:Play the Winning Hand - Watching Your Fortunes Grow in Skin Care 2Health News:Play the Winning Hand - Watching Your Fortunes Grow in Skin Care 3Health News:Chinese Pharma Market Continues to Grow at a 5-7% Rate in 2009; AMDL Remains on Track to Meet FY09 Financial Targets 2Health News:Chinese Pharma Market Continues to Grow at a 5-7% Rate in 2009; AMDL Remains on Track to Meet FY09 Financial Targets 3Health News:EAU Research Foundation organizes meeting in Amsterdam highlighting translational research results 2Health News:Archi-Tech InView Now Supports Managed Care Data, Offering an Interactive Dashboard for On-Demand Sales Planning and Reporting 2Health News:New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes 2Health News:New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes 3Health News:New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes 4